MedTrace Logo

Living Donor Liver Transplantation for Intrahepatic Cholangiocarcinoma

NCT06539377 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2024-08-06

No results posted yet for this study

Summary

This study is supposed to make liver transplantation available for treatment in well selected patients suffering from non-resectable intrahepatic cholangiocarcinoma. Donor organ shortage is currently the main problem for organ transplantation world-wide. Thus, the particular indication "non-resectable intrahepatic cholangiocarcinoma" is currently excluded in terms of transplantation. Given those circumstances, transplantation via living donation might be the best option. This procedure does not reduce the deceased donor organ supply because living donation is the primary treatment option in these patients (not subsidiary).

Conditions

  • Living Donor Liver Transplantation
  • Liver Transplantation
  • Neoadjuvant Therapy

Interventions

PROCEDURE

Living donor liver transplantation

Liver transplantation from living donor donation (SII/III as left-lateral donation during a "two stage"-procedure or left lobe donation or right lobe donation) in patients with unresectable intrahepatic cholangiocarcinoma.

Sponsors & Collaborators

  • Jena University Hospital

    lead OTHER

Principal Investigators

  • Utz Settmacher, Prof · Jena University Hospital

  • Falk Rauchfuss, Prof · Jena University Hospital

  • Laura Schwenk, MD · Jena University Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-09-01
Primary Completion
2030-10-01
Completion
2031-10-01

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06539377 on ClinicalTrials.gov